R&D Trends

bluebird bio, Duke collaborate on value-based payment framework for gene therapy

Tuesday, May 23, 2017

bluebird bio, a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that it will participate in a consortium led by Duke University’s Robert J. Margolis, M.D., Center for Health Policy to develop a broadly-supported path for value-based payment reform models for gene therapies and other innovative treatments.

[Read More]

X-Chem, Vertex enter genetic disease collaboration

Wednesday, May 17, 2017

X-Chem, a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced a collaboration with Vertex Pharmaceuticals. X-Chem will apply its proprietary DEXTM libraries, which contain more than 120 billion small molecules, toward the discovery of new drug leads against targets involved in multiple specialty diseases. Vertex will have the option to license lead-like hits discovered under the collaboration, and will be responsible for further development and commercialization of the resulting programs.

[Read More]

Rady Children’s Institute, Alexion partner on genetic disorders

Wednesday, May 17, 2017

The Rady Children’s Institute for Genomic Medicine (RCIGM) and Alexion Pharmaceuticals announced a strategic partnership to accelerate the diagnosis of critically ill newborns with rare genetic disorders. The collaboration combines the Institute’s genomic research expertise with Alexion data science and bioinformatics capabilities to advance precision medicine for infants in an intensive care setting.

[Read More]

Report: Spending on medicines totaled $450B in 2016

Thursday, May 4, 2017

In a QuintilesIMS report, various aspects of the market for medicines in the U.S. is highlighed—panning aggregate spending, key medicine categories, volumes, patient cost exposure, as well as an outlook to 2021. The report seeks to provide appropriate context and perspective around the complex factors that drive the level of spending on medicines and their role in our healthcare system.

[Read More]

AstraZeneca, Pieris collaborate for respiratory disease treatments

Wednesday, May 3, 2017

AstraZeneca announced a strategic collaboration in respiratory diseases with Pieris Pharmaceuticals to develop novel inhaled drugs that leverage Pieris’ Anticalin platform. Anticalin molecules are engineered proteins which can mimic antibodies by binding to sites either on other proteins or on small molecules. They are smaller than monoclonal antibodies, offering the potential of direct delivery to the lung.

[Read More]